Cipla and PULM dose first patient with Pulmazole in Phase 2 ABPA trial
  Author: Mateen Dalal

There is a substantial rise in the number of people affected with pulmonary diseases like asthma. Various pharmaceutical companies in the world are combining their capabilities to find treatments for serious pulmonary ...

Read More >>
AC Immune gets milestone payment to initiate Phase 2 trial of PI-2620
  Author: Mateen Dalal

As cases of neurodegenerative diseases like Alzheimer’s and Parkinson’s are on a rise, biopharmaceutical firms are actively engaging in developing new clinical drugs. Companies are also gaining increased fu...

Read More >>
AstraZenecas Farxiga gets fast track status to treat heart failure
  Author: Mateen Dalal

With heart related issues and number of people diagnosed with heart failure increasing substantially, the need to find a solution to this problem is growing considerably. Advanced technology, equipment and pharmaceutic...

Read More >>
Patient data from Oncopeptides’ Phase 2 trial to be showcased at IMW
  Author: Mateen Dalal

Patients having Relapsed-refractory multiple myeloma (RRMM) along with extramedullary disease (EMD) will be treated by Oncopeptides AB. In the comp...

Read More >>
Vertex- Scottish govt. sign cystic fibrosis treatment access contract
  Author: Mateen Dalal

As part of the 5-year agreement, Vertex will also be collecting real world data on these medicines. Vertex Pharmaceuticals Incorporated has reportedly announced tha...

Read More >>
Grünenthal and Mesoblast partner to develop innovative cell therapy
  Author: Mateen Dalal

Grünenthal will own the exclusive commercialization rights of allogeneic cell therapy candidate MPC-06-ID in Latin America and Europe. Grünenthal, a pharm...

Read More >>
Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints
  Author: Mateen Dalal

IN.PACT AV DCB showed encouraging results in the treatment of AV Fistulae Lesions in Renal Disease Patients at its last stage. Medtronic plc, one of the world&rsquo...

Read More >>
Oxurion concludes enrollment of patients for THR-687 Phase 1 trial
  Author: Nikita Chaurasia

12 patients with DME have enrolled into the study.   The results for the Phase 1 trial will be out by the end of 2019. ...

Read More >>
The Medicines Company declares positive results from Inclisiran trial
  Author: Nikita Chaurasia

The ORION-11 trial of inclisiran sodium 300 mg reached all secondary and primary endpoints with efficacy that is consistent with the findings from Phase 2 and 1 trials.   ...

Read More >>
STALICLA completes pre-IND meet with FDA on STP1 for patients with ASD
  Author: Nikita Chaurasia

Atrium Spectrum Disorder (ASD) affects 1 in 59 school children of 8-years in the United States. It is a common neurodevelopmental disorder, with a higher level of heterogeneity.  ...

Read More >>
Fitbit to support Singapore’s public health and smart nation programs
  Author: Mateen Dalal

Health population initiatives will be powered by Fitbit wearable devices and new Premium service Fitbit Inc., a San Francisco based tech company, has announced that...

Read More >>
Mallinckrodt states positive results of Terlipressin in HRS-1 patients
  Author: Nikita Chaurasia

The company announced positive results from its Phase 3 CONFIRM trial of terlipressin in Hepatorenal Syndrome Type 1. The study verified HRS-1 reve...

Read More >>
Sonnet to acquire Relief Therapeutics to develop atexakin alfa
  Author: Mateen Dalal

Sonnet proposes to pay 7,111,947 common shares and outstanding common stocks to Relief Therapeutics. Sonnet BioTherapeutics, Inc., a biotechnology company that deve...

Read More >>
Bayer buys BlueRock Therapeutics, marks stance cell therapy space
  Author: Mateen Dalal

Versant Ventures’ portfolio company, Bluerock Therapeutics acquired by Bayer AG for approximately USD 1 billion. This acquisition represents ...

Read More >>
Opthea unveils favorable results from Phase 2b wet AMD clinical trial
  Author: Mateen Dalal

Stable vision was achieved in 99.2% of subjects under the OPT-302 (2.0 mg) combination treatment, compared to 96.7% from the Lucentis control group at primary endpoint ...

Read More >>
Eloxx Pharmaceuticals initiates Phase 2 clinical trial for ELX-02
  Author: Mateen Dalal

Six patients will be registered for the trial and will be treated with ELX-02 for four weeks with three rising dose levels. Eloxx Pharmaceuticals, Inc., an American...

Read More >>
Squarex unveils Phase 2 results of SQX770 in recurrent herpes labialis
  Author: Mateen Dalal

The study involved around 139 subjects who had reported four or more episodes of herpes labialis in the past 12 months Squarex, a clinical-stage pharmaceutical comp...

Read More >>
Genentech’s Tecentriq® plus chemotherapy helps reduce risk of ABC
  Author: Mateen Dalal

Data will be demonstrated at an upcoming medical meeting and shared with health authorities globally, including the U.S. FDA (Food and Drug Administration). Genentech, a subsidiary ...

Read More >>
Rhodes Group & BCBSNM team up to improve patient outcome in New Mexico
  Author: Nikita Chaurasia

The collaboration aims to enhance patient outcomes within the New Mexico Centennial Care. BCBSNM is currently holds the accolade of being the forem...

Read More >>
MediciNova announces new research collaboration for MN-001 in Japan
  Author: Mateen Dalal

MediciNova will collaborate with the NCVC in Japan. Research would evaluate the effects of MN-001 on lipid metabolism and metabolic syndrome....

Read More >>
Brainscope declares to have surpassed primary endpoints in new study
  Author: Mateen Dalal

Brainscope has announced the successful completion of its nearly five year research contract with United States Department of Defense. The contract worth $9.9 million was to support the development and validation of an...

Read More >>
Oyster Point begins enrolment for Phase 3 ONSET-2 study of nasal spray
  Author: Mateen Dalal

The trial is designed to assess the efficacy and safety of OC-01 for treating dry eye disease Reports confirm that Oyster Point Pharma, a clinical-stage biopharmac...

Read More >>
Ligand buys AB Initio Biotherapeutics in a $12m cash transaction
  Author: Mateen Dalal

Ligand is eligible to receive royalties and milestones depending on potential future sales Ligand Pharmaceuticals Incorporated, a biopharmaceutical company focused ...

Read More >>
Canopy Rivers’ joint venture awarded Health Canada cultivation license
  Author: Mateen Dalal

PharmHouse’s greenhouse facility in Ontario is reportedly one of the largest in the world Canopy Rivers Inc, Canopy Growth Corp’s venture capital arm, h...

Read More >>
Detraxi to develop a new solution to reduce global blood shortages
  Author: Nikita Chaurasia

High income-growth countries like China will be the key recipient of the Detraxi biotechnology. Detraxi, a biotechnology company, is reportedly planning to develop ...

Read More >>
LifeMax certified for treating Netherton Syndrome with LM-030
  Author: Nikita Chaurasia

LifeMax Laboratories Inc a subsidiary of LifeMax Healthcare International Corporation, recently announced that a Novartis licensed investigational therapy, LM-030, has been granted pediatric disease designation by the FD...

Read More >>
Athira Pharma presents initial results from phase 1 trial of NDX-1017
  Author: Mateen Dalal

The company has been looking forward to initiate larger phase 2 trials. The clinical-stage company Athira Pharma, Inc. has reportedly announced preliminary data fro...

Read More >>
Ascentage Pharma declares first patient dosed in APG-2575 trial
  Author: Nikita Chaurasia

APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax. Ascentage Pharma has repor...

Read More >>
MediciNova confirms Phase 3 trial of ibudilast in progressive MS
  Author: Mateen Dalal

Ibudilast could be the best-in-disease drug for MS patients with unmet medical needs MediciNova, Inc., a biopharmaceutical company that develops novel therapeutics ...

Read More >>
CMIC becomes Align Clinical CRO member to enhance trial partnerships
  Author: Mateen Dalal

The teaming up of CMIC with other companies will improve the collaboration and execution of clinical studies CMIC Group, a leading Japanese Contract Research Organization (CRO) that provides complete range of pharmaceutica...

Read More >>
uniQure unveils Phase IIb study data of AMT-060 & AMT-061 therapy
  Author: Mateen Dalal

The data validates AMT-061 to be well-tolerated and capable of increasing FIX activity to normal in patients with hemophilia B. Renowned gene therapy firm, uniQure ...

Read More >>
Cantargia confirms enrollment in Phase IIa trial for CAN04 monotherapy
  Author: Mateen Dalal

All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dosage level Swedish biotech firm Cantargia has reportedly announced ful...

Read More >>
Gilead plans to submit New Drug Application for Filgotinib to USFDA
  Author: Nikita Chaurasia

Gilead Sciences, Inc., a biotechnology company recently provided an update about the investigational- filgotinib, selective JAK1 inhibitor, at a pre-NDA (New Drug Application) meeting with the USFDA, cite sources. ...

Read More >>
PeptiDream and Novartis to join forces on new peptide drug conjugate
  Author: Mateen Dalal

The partnership will bring the best first-in-class therapeutics and diagnostics for patients around the world PeptiDream, a public biopharmaceutical company that is...

Read More >>
AbbVie acquires Allergan for $63B foreseeing Humira patent expiration
  Author: Mateen Dalal

American biopharmaceutical firm AbbVie Inc has reportedly announced its decision to acquire Botox-maker Allergan Plc in a $63 billion deal. Apparently, this move would hand over the...

Read More >>
Applied Therapeutics unveils Phase 1/2 trial of Galactosemia treatment
  Author: Mateen Dalal

Galactosemia patients are in urgent need of treatment options and the company is committed to advancing AT-007 through clinical development Reports confirm that App...

Read More >>
RIBOMIC confirms positive results from SUSHI study in wet AMD patients
  Author: Mateen Dalal

Phase 1/2a trial of RBM-007 was successfully conducted, yielding top-line results   Seven out of nine subjects showed a considerable im...

Read More >>
Editas test CRISPR to treat beta-thalassemia & sickle cell disease
  Author: Nikita Chaurasia

Editas Medicine Inc., a U.S.-based pharmaceutical company recently announced results from trial of two different CRISPR-Cas9 genome editing strategies, one targeting the beta-globin locus and the other targeting the er...

Read More >>
Hemispherx treats first patient in clinical trial of Ampligen
  Author: Nikita Chaurasia

Hemispherx Biopharma Inc., a US-based biopharmaceutical company recently announced having treated its first patient with Ampligen in combination with Cisplatin & Pembrolizumab, in a phase 2 ovarian cancer clinical ...

Read More >>
Homology Medicines initiates Phase 1/2 trial for PKU gene therapy
  Author: Mateen Dalal

The firm’s drug (HMI-102) is expected to be the first gene therapy candidate for phenylketonuria (PKU) to enter clinics. Genetic drug maker, Homology Medicine...

Read More >>
Medtronic commences pivotal trial for Next-Generation CGM sensor
  Author: Mateen Dalal

Next-generation Guardian CGM is designed to lower sensor calibrations, improve and refine the accuracy and the overall performance of the system World’s large...

Read More >>
Cellenkos to test CK0801 for bone marrow failure syndromes treatment
  Author: Mateen Dalal

Cellenkos Inc., an early stage clinical biotechnology company recently announced initiation of Phase 1 clinical trial of CK0801 for treatment of bone marrow failure syndromes, including primary myelofibrosis, hypoplast...

Read More >>
Sanofi unveils Phase 3 trial results of isatuximab combination therapy
  Author: Mateen Dalal

The French multinational pharmaceutical company Sanofi has reportedly announced crucial Phase 3 ICARIA-MM trial results which revealed that isatuximab aided with dexamethasone and pomalidomide (isatuximab combination t...

Read More >>
Moderna announces data from Phase 1 mRNA cancer vaccine study
  Author: Nikita Chaurasia

The data revealed Moderna’s mRNA personalized cancer vaccine (PCV) mRNA-4157 to be well-tolerated at all tested doses and elicited neoantigen-specific T-cell responses. ...

Read More >>
Novartis unveils positive Phase III trial data for asthma treatment
  Author: Mateen Dalal

Novartis has recently unveiled the first clinical trial results from the phase III PLATINUM clinical development program evaluating the efficacy and safety of QMF149, which is an investigational, once a day, fixed dose...

Read More >>
Mesoblast submits BLA for remestemcel-L to treat aGVHD in children
  Author: Nikita Chaurasia

Mesoblast Limited has reportedly filed a rolling submission for Biologics License Application with the U.S Food and Drug Administration for remestemcel-L to treat steroid-refractory acute graft versus host disease in c...

Read More >>
Rexgenero expands manufacturing of cell-based CLI therapy REX-001
  Author: Nikita Chaurasia

A regenerative medicine company Rexgenero, creating advanced cell-based therapies for the treatment of critical limb ischaemia, has reportedly expanded the production of its lead development therapy REX-001 by partneri...

Read More >>
Eli Lilly’s mirikizumab scores positive data in Phase II Crohn’s study
  Author: Mateen Dalal

The company plans to initiate Phase III trials to assess mirikizumab’s benefit-risk profile to cure Crohn’s disease. U.S. pharma giant, Eli Lilly and Co...

Read More >>
Merck to acquire cancer drug maker Peloton Therapeutics for $1.05Bn
  Author: Mateen Dalal

The acquisition would help Merck strengthen its presence in the renal cell carcinoma space and support its cancer drug portfolio. U.S. pharmaceutical conglomerate, ...

Read More >>
BioXcel unveils data from Phase 1 study of receptor agonist BXCL501
  Author: Mateen Dalal

Sublingual administration of BXCL501 had achieved drug exposures that will be therapeutic for the acute treatment of agitation Reports confirm that BioXcel Therapeu...

Read More >>
Kazia to team up with U.S. oncology group for brain cancer drug trial
  Author: Mateen Dalal

A multi-centre phase-two study will represent the fourth clinical trial ongoing for Kazia’s GDC-0084 drug candidate Kazia Therapeutics Ltd, an Australian onco...

Read More >>
GSK, Zymeworks expand partnership for bispecific antibody development
  Author: Nikita Chaurasia

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopha...

Read More >>
Vertex, Kymera join forces for developing protein degradation drugs
  Author: Nikita Chaurasia

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incor...

Read More >>
Roche delays acquiring Spark as regulatory review process continues
  Author: Mateen Dalal

Roche, the leading Swiss pharma has pushed back its scheduled acquisition of the gene therapy specialist, Spark Therapeutics for third time in a row, as it waits for the U.S. government to complete regulatory review of...

Read More >>
Veeba Foods ventures into child nutrition segment with V-Nourish
  Author: Mateen Dalal

Condiments and sauce manufacturer Veeba Foods reportedly ventured into child nutrition segment with a new health beverage, V-Nourish. According to sources close to the matter, V-Nou...

Read More >>
Pfizer obtains FDA approval for oral heart drug costing $225K a year
  Author: Nikita Chaurasia

In May the drug received FDA breakthrough status and had lowered the risk of death for patients by 30% as compared to placebo The U.S. Food and Drug Administration ...

Read More >>
Cytokinetics declares FORTITUDE-ALS results from reldesemtiv study
  Author: Nikita Chaurasia

FORTITUDE-ALS did not attain statistical importance in its primary endpoint of change from baseline in SVC Patients who received reldesemtiv in FORTITUDE-AL...

Read More >>
Context Therapeutics begins Phase 2 Apristor trial for cancer patients
  Author: Mateen Dalal

The latest study will assess Apristor’s safety plus pharmacological profile in patients, besides the biomarker analyses, for exploring the drug’s predictive response factors. ...

Read More >>
Audentes exhibits new positive data from the ASPIRO clinical trial
  Author: Mateen Dalal

The leading American AAV-based genetic medicines company, Audentes Therapeutics Inc., has reportedly presented new positive data from ASPIRO, the AT132 Phase 1/2 clinical trial for the treatment of XLMTM (X-linked Myot...

Read More >>
Norton Healthcare & Select Medical tie up on outpatient rehabilitation
  Author: Nikita Chaurasia

In a recent turn of events, Norton Healthcare and Select Medical have reportedly declared signing a joint venture agreement intended to assimilate outpatient rehabilitation solutions in the Southern Indiana and Louisville metro provinces. ...

Read More >>
Oxurion & Bicycle Therapeutics declare full enrollment for DME study
  Author: Nikita Chaurasia

Bicycle Therapeutics, a biotech firm pioneering a new therapeutic class based on its patented bicyclic peptide or Bicycle® platform, and Oxurion have recently declared complete registration of Oxurion’s Phase...

Read More >>
Precision BioSciences doses first patient in CAR T cell therapy trial
  Author: Nikita Chaurasia

Precision is creating PBCAR0191 in partnership with Servier, a multinational pharmaceutical firm   The company believes that the patien...

Read More >>
BioTime to present OpRegen® Phase I/IIa study outcomes at ARVO 2019
  Author: Nikita Chaurasia

BioTime Incorporation, a clinical stage biotechnology firm developing newfangled cellular treatments, has recently declared that updated outcomes from a Phase I/IIa clinical study of OpRegen®, its chief product can...

Read More >>
FDA approves Gelesis prescription weight-loss drug Plenity for adults
  Author: Mateen Dalal

Plenity is has been cleared for obese or overweight adults having a body mass index of at least 25 Reports confirm that the U.S. Food and Drug Administration (FDA) ...

Read More >>
Assembly Biosciences reveals data from Phase 2a studies of ABI-H0731
  Author: Mateen Dalal

The data received to date is directionally correct and reduction in HBeAg and HBsAg have been observed in some individuals in both studies. U.S. based clinical-stag...

Read More >>
Inscripta raises additional $20 million in Series C financing round
  Author: Nikita Chaurasia

Inscripta is working to develop a full suite of gene-editing tools (reagents, software and instruments) to increase the efficiency and speed of CRISPR-based gene-editing ...

Read More >>
Cyclacel unveils Phase 1 clinical data for its breast cancer treatment
  Author: Mateen Dalal

·         The data was presented at the American Association for Cancer Research Annual Meeting 2019 ·  ...

Read More >>
Imvax unveils positive results from clinical trial of IGV-001 vaccine
  Author: Nikita Chaurasia

Clinical-stage biotechnology company Imvax, Inc., committed to creating novel patient-specific vaccines and immunotherapy strategies, has reportedly attained positive results from an ongoing Phase 1b clinical trial tha...

Read More >>
Partners HealthCare to fully integrate its EHR system with MassPAT
  Author: Mateen Dalal

Partners Healthcare has now become the first healthcare network to have the tool immediately available to doctors at the point-of-care in Massachusetts. Partners He...

Read More >>
Biogen to wholly acquire gene therapy firm Nightstar Therapeutics
  Author: Mateen Dalal

Nightstar’s agreement with Biogen will give the company the platform and resources it needs to expand its mission to restore sight in patients with inherited retinal diseases. ...

Read More >>
Merck offers $5-9B for Versum Materials to challenge bid from Entegris
  Author: Mateen Dalal

The company is apparently looking to buy the electronic materials maker for bolstering its Performance Materials division Merck KGaA, the laboratory supplies provid...

Read More >>
MPM Capital secures $400M to finance innovative biotech startups
  Author: Mateen Dalal

The fund would reportedly contribute toward disruptive scientific developments across a spate of therapeutic areas such as immunology, oncology, and neurosciences. ...

Read More >>
AC Immune starts enrolling patients for next Phase 2 trial of anti-Tau
  Author: Nikita Chaurasia

The antibody, called as MTAU9937A, RO7105705, is also being assessed by Genentech in a different Phase 2 trial Anti-Tau monoclonal antibody was det...

Read More >>
U.S. FDA to clampdown potentially perilous dietary supplements
  Author: Mateen Dalal

Council for Responsible Nutrition welcomed the action against companies that have tarnished consumer confidence for all legitimate products. The U.S. Food and Drug ...

Read More >>
Merck to invest $70m for R&D facility expansion in Massachusetts
  Author: Mateen Dalal

The building construction is scheduled to be completed in 2021 and is designed to offer office space, wet labs and a cafeteria. Merck, one of the leaders in the pha...

Read More >>
Thermo Fisher to collaborate with Torque to develop Slipstream™
  Author: Mateen Dalal

The Torque-Thermo Fisher manufacturing facility is expected to come online by the end of 2019. Thermo Fisher Scientific Inc., the biotechnology products development...

Read More >>
UK university uses graphene to develop lung cancer detection device
  Author: Mateen Dalal

The new device possesses the potential to detect specific lung cancer markers at the earliest stage possible. In what may seem to a pathbreaking revolutionary finding i...

Read More >>
U.S. FDA approves first generic drug for asthma and COPD treatment
  Author: Mateen Dalal

The generic drug will mean low cost but high-quality drug access to people suffering from chronic respiratory and lung diseases. The U.S. Food and Drug Administrati...

Read More >>
Roche to abandon Alzheimer’s drug crenezumab following failed trials
  Author: Nikita Chaurasia

The news from Roche marks another failure in developing drugs for Alzheimer’s after many other drugmakers have stopped trials of prospective treatments. Roche...

Read More >>
AstraZeneca inks a value-based agreement with UPMC Health Plan
  Author: Mateen Dalal

The deal links reimbursement for the blood thinner to the cardiovascular outcomes of patients.   Sources familiar with the development ...

Read More >>
Purdue Pharma teams up with Alivio Therapeutics to advance ALV-107
  Author: Mateen Dalal

Purdue Pharma L.P., the Connecticut-based pharmaceutical company, has reportedly announced that it has signed a partnership agreement with Alivio Therapeutics to advance one of its product candidates via clinical devel...

Read More >>
Abcam acquires California-based antibodies developer Calico Biolabs
  Author: Nikita Chaurasia

U.K. biotech firm Abcam has recently confirmed the acquisition of Calico Biolabs, a specialist in rabbit monoclonal antibodies based out of California. Calico is known to provide custom, high-quality recombinant rabbit...

Read More >>
Basilea & Roche to jointly study novel treatment for urothelial cancer
  Author: Nikita Chaurasia

The planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer. ...

Read More >>